Clinical trials: Neoadjuvant Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC
Despite the clinical success of immune checkpoint blockade (ICB), in neoadjuvant setting, there is still a lack of valid data for operable NSCLC in the real world.
- Trial name
- NeoR-World (NCT05974007)
- Testing
- Neoadjuvant immunochemotherapy, Neoadjuvant chemotherapy
- Where
- China
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Stage III, Non-small Cell Lung Cancer
Neoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung Cancer
This is a prospective, one-arm, phase II study aimed at evaluating tislelizumab combined with platinum-containing dual-drug chemotherapy as a neoadjuvant treatment, supplemented with tislelizumab after surgery in patients with…
- Trial name
- NCT04865705
- Testing
- tislelizumab
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- West China Hospital
Non-small Cell Lung Cancer, Neoadjuvant Therapy
Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer
Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer, Neoadjuvant Therapy, Radiotherapy, Immunotherapy
- Trial name
- NCT06065813
- Testing
- Toripalimab, Conventional segmental radiotherapy, opreation
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Northern Jiangsu People's Hospital
NSCLC Stage IIIB, NSCLC Stage IIIC
Clinical Outcomes of Tislelizumab Combined With Chemotherapy as Induction Therapy in Stage III (cTNM-IIIB/IIIC) NSCLC
This is an observational study evaluating the clinical characteristics, treatment patterns, and clinical outcomes in Stage III (cTNM-IIIB/IIIC) Non-Small Cell Lung Cancer.Patients meeting inclusion and exclusion criteria were…
- Trial name
- NCT06829641
- Testing
- Tislelizumab Combined with Chemotherapy,
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- West China Hospital
Non-Small-Cell Lung Cancer, Carcinoma
Locally Invasive NSCLC Treated With NEo-Adjuvant Stereotactic Body RadioTherapy and REsection
Despite improved staging and operative techniques, the rate of incomplete resection (R1) of NSCLC has remained significant over the last decades.
- Trial name
- LINNEARRE-I (NCT02433574)
- Testing
- Neoadjuvant Stereotactic body radiation (SBRT)
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Juravinski Cancer Center
Lung Cancer, Nonsmall Cell
Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
This is a prospective, randomized, single-site, open-label Phase II trial of neoadjuvant pembrolizumab (3 cycles) followed by surgery, versus concomitant neoadjuvant pembrolizumab with platinum doublet chemotherapy (3 cycles)…
- Trial name
- NCT04638582
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- Canada
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Lung Cancer Non-small Cell, Colorectal Cancer
Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer
This single-center cohort study integrates humoral immune response profiling (Phage ImmunoPrecipitation Sequencing, PhIP-seq) with circulating cell-free DNA (cfDNA) genomic and epigenomic features, exosome transcriptomics, and…
- Conditions
- Lung Cancer Non-small Cell, Colorectal Cancer, Stomach Cancer, Hepatocellular Carcinoma
- Trial name
- NCT07880106
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Non-Small Cell Carcinoma of Lung, Gut Microbiomes
Microbiota in Neoadjuvant Chemoimmunotherapy for NSCLC
Locally advanced lung cancer (LALC) has poor prognosis despite multimodal therapies. Neoadjuvant chemoimmunotherapy is now standard for resectable stage II-IIIB NSCLC, but patient responses vary.
- Conditions
- Non-Small Cell Carcinoma of Lung, Gut Microbiomes, Neoadjuvant Chemoimmunotherapy
- Trial name
- NCT07752589
- Testing
- Neoadjuvant chemoimmunotherapy
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Guangdong Provincial People's Hospital
Non Small Cell Lung Cancer, Lung Cancer
Phase II Lung Metcore - Preoperative Metformin for Lung Cancer
This is a phase II single centre open label single arm pre-operative window of metformin treatment in stage I-IIIa Non small cell lung cancer.
- Trial name
- Metcore (NCT03086733)
- Testing
- Metformin
- Where
- 2 sites in Canada
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto